Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Pomalidomide clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Pomalidomide as a study intervention. Browse Pomalidomide recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
204
Shown on this page
12
Current sort
Recently updated
Therapy scope
Pomalidomide
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Pomalidomide. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 121–132 of 204 matching trials for Pomalidomide.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Completed Phase 1Phase 2 Interventional

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

NCT02206425
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Melphalan, Prednisone, Cyclophosphamide, Dexamethasone, Ascorbic acid, PLD, Lenalidomide, Pomalidomide
Drug · Dietary Supplement
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
12
States / cities
Bakersfield, California • Concord, California • Encinitas, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 22, 2026, 8:01 AM EDT
Completed Phase 2 Interventional Results available

Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia

NCT02547662
View directory record Official record
Conditions
Plasma Cell Leukemia, Plasma Cell Myeloma, Plasmacytoma
Interventions
Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis, Pomalidomide
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Rochester, Minnesota • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 22, 2026, 8:01 AM EDT
Not listed Phase 1Phase 2 Interventional

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma

NCT04942067
View directory record Official record
Conditions
Multiple Myeloma, Amyloidosis
Interventions
APG-2575+ Pd, APG-2575 + DRd
Drug
Lead sponsor
Ascentage Pharma Group Inc.
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Jacksonville, Florida • New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 22, 2026, 8:01 AM EDT
Terminated Phase 2 Interventional Results available

Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients

NCT04843579
View directory record Official record
Conditions
Myeloma Multiple, Myeloma, Refractory Multiple Myeloma
Interventions
Selinexor, Clarithromycin, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 74 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 22, 2026, 8:01 AM EDT
Completed Phase 2 Interventional Results available

Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma

NCT03202628
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis, Pomalidomide
Procedure · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 22, 2026, 8:01 AM EDT
Withdrawn Phase 1Phase 2 Interventional

A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.

NCT05205252
View directory record Official record
Conditions
Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy
Interventions
Tazemetostat, Tafasitamab, Lenalidomide, Acalabrutinib, Daratumumab (Intravenously), Mosunetuzumab, Daratumumab (Subcutaneously), Hyaluronidase-Fihj, Pomalidomide, Dexamethasone 20mg
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Santa Fe, California • Bolivar, Missouri • East Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 22, 2026, 8:01 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

NCT01734928
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pomalidomide, Bortezomib, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
92
States / cities
Mobile, Alabama • Tucson, Arizona • Berkeley, California + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Oct 22, 2026, 8:01 AM EDT
Terminated Phase 1 Interventional

First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD

NCT01728259
View directory record Official record
Conditions
Light Chain Deposition Disease, Primary Systemic Amyloidosis
Interventions
pomalidomide, bortezomib, dexamethasone, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Denver, Colorado • Boston, Massachusetts • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 22, 2026, 8:01 AM EDT
Completed Phase 3 Interventional Results available

An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma

NCT02726581
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Nivolumab, Elotuzumab, Pomalidomide, Dexamethasone
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
72
States / cities
Birmingham, Alabama • Mobile, Alabama • Fayetteville, Arkansas + 65 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 22, 2026, 8:01 AM EDT
Terminated Phase 1 Interventional

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

NCT04895410
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lemzoparlimab, Dexamethasone, Carfilzomib, Pomalidomide, Daratumumab
Biological · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
12
States / cities
Miami, Florida • Tampa, Florida • Louisville, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 22, 2026, 8:01 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

NCT03439280
View directory record Official record
Conditions
Relapsed/Refractory, Multiple Myeloma
Interventions
Mezagitamab, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Duarte, California • St Louis, Missouri • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 22, 2026, 8:01 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma

NCT02807454
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Durvalumab, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
15
States / cities
Duarte, California • Los Angeles, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 22, 2026, 8:01 AM EDT

About this Pomalidomide clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Pomalidomide as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Pomalidomide.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Pomalidomide.